Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse back in January – reveals his strategy:
The One Ticker Retirement Plan… How to make all the money you need – in any market – using a single stock. Click here for the name of the ticker…
>>>
pixel

Brian Durkin Biography and Net Worth

VP of AbbVie


Brian L. Durkin serves as Vice President, Controller of the Company. Mr. Durkin previously served as Vice President, Internal Audit from 2016 to 2018. Prior to joining AbbVie, he served as Vice President of Finance and Division Controller for Abbott’s Vision Care business from 2009 to 2016 and Controller Pharmaceutical Research and Development from 2005 to 2009. Mr. Durkin joined Abbott in 1986.

What is Brian L. Durkin's net worth?

The estimated net worth of Brian L. Durkin is at least $2.05 million as of March 20th, 2020. Mr. Durkin owns 15,294 shares of AbbVie stock worth more than $2,052,608 as of October 1st. This net worth estimate does not reflect any other assets that Mr. Durkin may own. Learn More about Brian L. Durkin's net worth.

How do I contact Brian L. Durkin?

The corporate mailing address for Mr. Durkin and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Brian L. Durkin's contact information.

Has Brian L. Durkin been buying or selling shares of AbbVie?

Brian L. Durkin has not been actively trading shares of AbbVie in the last ninety days. Most recently, Brian L. Durkin sold 18,628 shares of the business's stock in a transaction on Wednesday, March 9th. The shares were sold at an average price of $150.01, for a transaction totalling $2,794,386.28. Learn More on Brian L. Durkin's trading history.

Who are AbbVie's active insiders?

AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.

Are insiders buying or selling shares of AbbVie?

During the last year, insiders at the sold shares 17 times. They sold a total of 1,048,944 shares worth more than $146,558,841.47. The most recent insider tranaction occured on May, 23rd when Vice Chairman Michael Severino sold 79,801 shares worth more than $12,041,970.90. Insiders at AbbVie own 0.1 % of the company. Learn More about insider trades at AbbVie.

Information on this page was last updated on 5/23/2022.

Brian L. Durkin Insider Trading History at AbbVie

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/9/2022Sell18,628$150.01$2,794,386.28View SEC Filing Icon  
12/20/2021Sell11,790$128.51$1,515,132.90View SEC Filing Icon  
3/20/2020Buy3,750$68.82$258,075.0015,294View SEC Filing Icon  
3/18/2020Buy2,200$68.18$149,996.0015,294View SEC Filing Icon  
3/25/2019Sell475$79.69$37,852.759,121View SEC Filing Icon  
See Full Table

Brian L. Durkin Buying and Selling Activity at AbbVie

This chart shows Brian L Durkin's buying and selling at AbbVie by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AbbVie Company Overview

AbbVie logo
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Read More

Today's Range

Now: $134.21
Low: $134.09
High: $142.33

50 Day Range

MA: $141.00
Low: $134.21
High: $151.15

2 Week Range

Now: $134.21
Low: $106.86
High: $175.91

Volume

15,336,473 shs

Average Volume

6,873,221 shs

Market Capitalization

$237.30 billion

P/E Ratio

19.01

Dividend Yield

3.95%

Beta

0.72